Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicamtiv Drug-Drug Interaction Study with Midazolam in HFrEF
NCT05952089Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danicamtiv in heart failure with reduced ejection fraction (HFrEF), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration time curve extrapolated to infinite time and 1 more. Started Aug 2023; status: completed.
02
Drugs
danicamtiv
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05952089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952089.